The pharmacogenetics of imatinib 英文参考文献.docVIP

Dulucq and Krajinovic Genome Medicine 2010,2:85 /content/2/11/85 REVIEW The pharmacogenetics of imanitib Stéphanie Dulucq and Maja Krajinovic * 1 2 protein has a role in leukemogenesis [1]. IM occupies the ATP-binding pocket of the ABL kinase domain; this prevents a change in conformation of the protein that would otherwise convert the molecule to its active form, and IM binding thereby leads to the apoptosis of target cells. Abstract Imatinib mesylate (IM), a tyrosine kinase inhibitor, is one of the ?rst molecular